Table 3.
HIV-Related Health Status at Baselinea
| Among Analysis Population | Among Participants on INSTIs at Entry | ||||||
|---|---|---|---|---|---|---|---|
| Characteristic | Total (N = 4500) | Non-INSTI-Containing Entry Regimen (N = 2652) | INSTI-Containing Entry Regimen (N = 1848) | Entry INSTI = DTG (N = 882) | Entry INSTI = EVG (N = 643) | Entry INSTI = Otherb (N = 323) | |
| HIV-RelatedHealthStatus | |||||||
| Nadir CD4 count (cells/mm³) | <50 | 854 (19%) | 461 (17%) | 393 (21%) | 205 (23%) | 103 (16%) | 85 (26%) |
| 50–199 | 1210 (27%) | 701 (26%) | 509 (28%) | 236 (27%) | 178 (28%) | 95 (29%) | |
| 200–349 | 1188 (26%) | 755 (28%) | 433 (23%) | 201 (23%) | 170 (26%) | 62 (19%) | |
| 350+ | 1079 (24%) | 640 (24%) | 439 (24%) | 212 (24%) | 162 (25%) | 65 (20%) | |
| Unknown | 169 (4%) | 95 (4%) | 74 (4%) | 28 (3%) | 30 (5%) | 16 (5%) | |
| Total ART use duration (years) | Mean (s.d.) | 11 (7) | 10 (6) | 12 (8) | 12 (8) | 10 (7) | 14 (7) |
| Median (Q1, Q3) | 10 (5, 16) | 9 (5, 15) | 11 (6, 18) | 11 (6, 18) | 8 (4, 15) | 15 (8, 20) | |
| <5 | 978 (22%) | 576 (22%) | 402 (22%) | 189 (21%) | 181 (28%) | 32 (10%) | |
| 5–10 | 1288 (29%) | 825 (31%) | 463 (25%) | 205 (23%) | 183 (28%) | 75 (23%) | |
| 10+ | 2232 (50%) | 1250 (47%) | 982 (53%) | 487 (55%) | 279 (43%) | 216 (67%) | |
| Unknown | 2 (<0.5%) | 1 (<0.5%) | 1 (<0.5%) | 1 (<0.5%) | 0 (0%) | 0 (0%) | |
| Duration of Entry ART Regimen (years) | Mean (s.d.) | 4 (3) | 5 (4) | 2 (2) | 2 (1) | 2 (1) | 4 (3) |
| Median (Q1, Q3) | 3 (1, 6) | 4 (2, 8) | 1 (1, 3) | 1 (1, 2) | 1 (1, 2) | 4 (2, 6) | |
| 6 months <1 | 815 (18%) | 266 (10%) | 549 (30%) | 287 (33%) | 218 (34%) | 44 (14%) | |
| 1–3 | 1697 (38%) | 766 (29%) | 931 (50%) | 497 (56%) | 359 (56%) | 75 (23%) | |
| 3–5 | 706 (16%) | 487 (18%) | 219 (12%) | 84 (10%) | 60 (9%) | 75 (23%) | |
| 5+ | 1282 (28%) | 1133 (43%) | 149 (8%) | 14 (2%) | 6 (1%) | 129 (40%) | |
| CD4 count (cells/mm³) | 500+ | 3118 (69%) | 1900 (72%) | 1,218 (66%) | 568 (64%) | 440 (68%) | 210 (65%) |
| <500 | 1382 (31%) | 752 (28%) | 630 (34%) | 314 (36%) | 203 (32%) | 113 (35%) | |
| HIV-1 RNA (copies/mL) | 400+ | 74 (2%) | 40 (2%) | 34 (2%) | 14 (2%) | 11 (2%) | 9 (3%) |
| <400 | 4047 (98%) | 2308 (98%) | 1739 (98%) | 838 (98%) | 604 (98%) | 297 (97%) | |
Abbreviations: ART, antiretroviral therapy; DTG, dolutegravir; EVG, elvitegravir; HIV, human immunodeficiency virus; INSTI, integrase-strand transfer inhibitor; RNA, ribonucleic acid; s.d., standard deviation.
a
All statistics are calculated with data collected from participants.
b
“Other” INSTI includes participants on raltegravir or bictegravir.